Pitobrutinib side effects

Pitobrutinib, a kinase inhibitor, has attracted much attention in recent years in the treatment of mantle cell lymphoma (MCL). The drug is specifically targeted at adult patients whose disease has relapsed or been difficult to control despite at least two systemic treatments, including a BTK inhibitor. Pitobrutinib interferes with the growth and spread of cancer cells by inhibiting specific kinase activity, thereby providing new treatment opportunities for patients.

However, like many anticancer drugs, the use of pitobrutinib may be associated with a range of side effects. Common side effects include bruising, tiredness, diarrhea, and swelling in various parts of the body. In addition, patients may experience muscle and joint pain, bone pain, and infection-like symptoms such as fever and chills. Cough, chest pain, and shortness of breath are also side effects that should not be ignored.

Of particular note is the potential for severe allergic reactions to pitobrutinib. People should seek emergency medical help immediately if they develop hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

In addition to allergic reactions, pitobrutinib can cause a range of serious cardiovascular and blood system problems. Symptoms such as chest pressure, abnormal heartbeat, palpitations, and shortness of breath require patients and doctors to be highly vigilant. Also, any signs of infection, internal bleeding, or abnormally low blood cell counts may be signs of drug side effects and require immediate medical attention.

Although pitobrutinib brings new hope to patients with relapsed or refractory mantle cell lymphoma, its side effects cannot be ignored. Patients should pay close attention to their physical condition during medication and communicate with their doctors in a timely manner to ensure the safety and effectiveness of treatment.

xa0

Reference: https://www.drugs.com/pirtobrutinib.html